Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Pila Pharma AB (“Pila Pharma” or “the Company”) is developing the drug candidate XEN-D0501 for obesity, type 2 diabetes, and erythromelalgia, an orally administered, small-molecule TRPV1 antagonist aiming to reduce hyperactive inflammation linked to metabolic disorders. The candidate is considered scalable and provides a differentiated alternative to current therapies, expected to be essential in making obesity treatment more accessible. Analyst Group argues that the potential relative to the associated risks is not reflected in the current valuation, and based on an rNPV model, a present value of SEK 5.7 (6.3) per share is derived in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)
This is a press release from Analyst Group regarding the publication of an analysis on Pila Pharma. Readers may assume that Analyst Group has received compensation for making the commentary. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.